Trial Speculation Heats Up: Social media chatter centers on SELLAS Life Sciences amid rising anticipation for its phase 3 REGAL trial data. Traders point to elevated short interest and potential catalysts that could drive momentum in the coming weeks.
Dip Buying Emerges: Recent price weakness has drawn attention as some participants note dips are being absorbed quickly. Discussions emphasize ongoing volatility without clear resolution on near-term direction.
Short Interest Focus: Analysts on social media highlight the stock's short float and possible squeeze scenarios tied to upcoming events. Sentiment remains divided between optimism for binary outcomes and caution over execution risks.
Note: This discussion summary was generated from an AI condensation of post data.
SELLAS Life Sciences Hedge Fund Activity
We have seen 108 institutional investors add shares of SELLAS Life Sciences stock to their portfolio, and 27 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE STREET CORP added 6,208,185 shares (+283.7%) to their portfolio in Q1 2026, for an estimated $26,260,622
- BLACKROCK, INC. added 4,657,356 shares (+61.8%) to their portfolio in Q1 2026, for an estimated $19,700,615
- JONES FINANCIAL COMPANIES LLLP added 1,245,834 shares (+290.2%) to their portfolio in Q1 2026, for an estimated $5,269,877
- MILLENNIUM MANAGEMENT LLC removed 1,228,325 shares (-88.5%) from their portfolio in Q1 2026, for an estimated $5,195,814
- GEODE CAPITAL MANAGEMENT, LLC added 835,269 shares (+27.1%) to their portfolio in Q1 2026, for an estimated $3,533,187
- UBS GROUP AG added 696,692 shares (+1429.8%) to their portfolio in Q1 2026, for an estimated $2,947,007
- MARSHALL WACE, LLP added 696,494 shares (+52.0%) to their portfolio in Q1 2026, for an estimated $2,946,169
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
